TriangleNCT04824794 · MORE INFO
Limitations, agreements, and source contact
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- certain Agreement
- pi Sponsor Employee
- false
- restrictive Agreement
- true
- limitations And Caveats
- description
- The overall study was terminated early. The AML Dose Escalation cohort and the DLBCL Expansion Part A cohort were terminated early due to enrollment challenges. The anti-CD38 mAb-refractory RRMM cohort and the R/R AML cohort in Expansion Part A were not opened.
- point Of Contact
- clinicaltrials@genmab.com
- organization
- Genmab
- phone
- +45 7020 2728
- title
- CLINICAL TRIAL INFORMATION
Complete source fields
- certain Agreement
- pi Sponsor Employee
- false
- restrictive Agreement
- true
- limitations And Caveats
- description
- The overall study was terminated early. The AML Dose Escalation cohort and the DLBCL Expansion Part A cohort were terminated early due to enrollment challenges. The anti-CD38 mAb-refractory RRMM cohort and the R/R AML cohort in Expansion Part A were not opened.
- point Of Contact
- clinicaltrials@genmab.com
- organization
- Genmab
- phone
- +45 7020 2728
- title
- CLINICAL TRIAL INFORMATION
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice